Gadoversetamide
![]() | |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | V08CA06 (WHO) |
Pharmacokinetic data | |
Protein binding | Nil |
Metabolism | Nil |
Biological half-life | 80 to 120 minutes |
Excretion | Renal |
Identifiers | |
CAS Number |
131069-91-5 ![]() |
PubChem (CID) | 6435809 |
DrugBank |
DB00538 ![]() |
ChemSpider |
392041 ![]() |
UNII |
RLM74T3Z9D ![]() |
KEGG |
D01646 ![]() |
ChEMBL |
CHEMBL1200457 ![]() |
Chemical and physical data | |
Formula | C20H34GdN5O10 |
Molar mass | 661.77 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
![]() ![]() |
Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.[1] It is marketed under the trade name OptiMARK.
Notes
- ↑ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Retrieved 2007-03-23.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.